As Intuitive Surgical gets FDA clearance for its next-gen robotic surgery system, ISRG stock teases a new breakout.
While the biotechnology sector may receive most of the attention under the broad healthcare umbrella, investors ought to spare some love for medical technology stocks. The enterprises undergirding these securities offer tremendously positive potential for overall patient outcomes.
Intuitive Surgical (ISRG) shares gain on the back of growth in the da Vinci treatment volume and raised procedure prices.
Intuitive Surgical, Inc. (ISRG) concluded the recent trading session at $404.85, signifying a +1.62% move from its prior day's close.
The recommendations of Wall Street analysts are often relied on by investors when deciding whether to buy, sell, or hold a stock. Media reports about these brokerage-firm-employed (or sell-side) analysts changing their ratings often affect a stock's price.
Intuitive Surgical's (ISRG) da Vinci procedure volume, coupled with strong Ion procedure growth, is fueling the rally in the company???s share price.
Automation continues to be a key driving force of technological innovation in the 21st century. Older industrial sectors have relied on automation for driving efficiencies across the use of various equipment.